The value of HPV vaccination | Nature Medicine

Access through your institution Buy or subscribe PERSISTENT INFECTION WITH HIGH-RISK TYPES OF HUMAN PAPILLOMAVIRUS (HPV) CAUSES ALMOST ALL CERVICAL CANCERS. TWO HPV VACCINES HAVE BEEN

LICENSED FOR PROPHYLACTIC VACCINATION IN MANY COUNTRIES AND HAVE BEEN HIGHLY EFFECTIVE AT PREVENTING INFECTION BY THE VACCINE-TARGETED HPV TYPES. TWO RECENT PAPERS DESCRIBE THE FOUR-YEAR,

END-OF-STUDY DATA FROM A LARGE-SCALE TRIAL OF CERVARIX, A VACCINE THAT TARGETS THE MOST PREVALENT ONCOGENIC HPV TYPES 16 AND 18, IN WOMEN AGED 15–25 YEARS 1, 2 . THE RESULTS INDICATE THAT

THE VACCINE HAS HIGH EFFICACY AGAINST CERVICAL PRECANCER DEVELOPMENT AND IS CROSS PROTECTIVE AGAINST NONVACCINE ONCOGENIC HPV TYPES. WE ASKED FOUR EXPERTS TO COMMENT ON THIS TRIAL AND THE

IMPLICATIONS FOR VACCINATION AND CERVICAL CANCER SCREENING POLICIES. JANE KIM This is a preview of subscription content, access via your institution RELEVANT ARTICLES Open Access articles

citing this article. * INTRODUCTION AND SUSTAINED HIGH COVERAGE OF THE HPV BIVALENT VACCINE LEADS TO A REDUCTION IN PREVALENCE OF HPV 16/18 AND CLOSELY RELATED HPV TYPES * K Kavanagh * , K G

J Pollock *  … M Donaghy _British Journal of Cancer_ Open Access 15 April 2014 ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online

access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which

are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Lehtinen, M. et al.

_Lancet Oncol._ published online, 10.1016/S1470-2045(11)70286-8 (8 November 2011). * Wheeler, C. et al. _Lancet Oncol._ published online, 10.1016/S1470-2045(11)70287-X (8 November 2011). *

Brown, D.R. et al. _J. Infect. Dis._ 199, 926–935 (2009). Article  Google Scholar  * Hoy, T., Singhal, P.K., Willey, V.J. & Insinga, R.P. _Curr. Med. Res. Opin._ 25, 2343–2351 (2009).

Article  Google Scholar  * Goldie, S.J. et al. _Vaccine_ 26, 4080–4093 (2008). Article  Google Scholar  * Muñoz, N. et al. _J. Natl. Cancer Inst._ 102, 325–339 (2010). Article  Google

Scholar  * Lowy, D.R., Solomon, D., Hildesheim, A., Schiller, J.T. & Schiffman, M. _Cancer_ 113, Suppl. 7, 1980–1993 (2008). Article  Google Scholar  * Brotherton, J.M. et al. _Lancet_

377, 2085–2092 (2011). Article  Google Scholar  * Gee, J. et al. _Vaccine_ 29, 8279–8284 (2011). Article  Google Scholar  * Einstein, M.H. et al. _Hum. Vaccin._ 7, 1359–1373 (2011). Article

  CAS  Google Scholar  * Romanowski, B. et al. _Lancet_ 374, 1975–1985 (2009). Article  CAS  Google Scholar  * Kjær, S.K., Frederiksen, K., Munk, C. & Iftner, T. _J. Natl. Cancer Inst._

102, 1478–1488 (2010). Article  Google Scholar  * Barr, E. et al. _Am. J. Obstet. Gynecol._ 198, 261.e1–261.e11 (2008). Article  Google Scholar  * Centers for Disease Control and Prevention.

_MMWR Morb. Mortal. Wkly. Rep._ 59, 626–629 (2010). Download references ETHICS DECLARATIONS COMPETING INTERESTS K.K.S.-M. is on the scientific and clinical advisory board and has stock

options for OncoHealth, a company developing diagnostic tests for cervical cancer screening. D.R.L. is an inventor on US government–owned human papilloma virus vaccine patents that are

licensed to Glaxo-Smith Kline and Merck and is entitled to limited royalties as specified by law. C.J.M.M. is chief scientific officer of ISA Pharmaceuticals. This company develops synthetic

therapeutic vaccines. In theory, such vaccines can also possess preventive activity, although no preventive activity against HPV16 or HPV18 has been shown by ISA. RIGHTS AND PERMISSIONS

Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE The value of HPV vaccination. _Nat Med_ 18, 28–29 (2012). https://doi.org/10.1038/nm0112-28 Download citation * Published: 06

January 2012 * Issue Date: January 2012 * DOI: https://doi.org/10.1038/nm0112-28 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable

link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative